1356997-45-9

Upstream product

• 705-31-7 4-trifluoromethylphenylacetylene 
• 34091-51-5 5-iodo-1-methyl-1H-pyrazole 

Downstream Products

• 1356997-44-8 1-methyl-5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1H-pyrazole 
• 1356997-87-9 4-iodo-1-methyl-5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1H-pyrazole 
• 1356996-31-0 4-[(1-methyl-5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-yl)ethynyl]benzenesulfonamide 
• 1359029-98-3 4-(1H-imidazol-4-yl)-1-methyl-5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1H-pyrazole 
• 1359029-99-4 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1H-pyrazole 
• 1359029-93-8 2-(1-methyl-5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-yl)-1,3-oxazole-4-yl trifluoromethanesulfonate 
• 1359029-95-0 2-(1-methyl-5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-yl)-1,3-oxazol-4(5H)-one 
• 1359029-94-9 1-methyl-5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1H-pyrazole-4-carboxamide 
• 1359029-55-2 ethyl 1-methyl-5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-carboxylate 
• 1359029-37-0 1-methyl-5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1H-pyrazole-4-carbonitrile 
• 1359029-30-3 4-({2-[(1-methyl-5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-yl)carbonyl]hydrazinyl}carbonyl)benzenesulfonamide 
• 1359029-69-8 1-methyl-5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-carboxylic acid 
• 1402232-45-4 N,1-dimethyl-5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-carbohydrazide 
• 1359027-37-4 N,N-bis[2-(dimethylamino)ethyl]-3-[5-(1-methyl-5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl]benzenesulfonamide 

Relevant academic research and scientific papers

ETHINYL-PYRAZOLE DERIVATIVE

Provided is a novel compound represented by formula [I] or a pharmaceutically acceptable salt thereof having antagonistic activity against group II metabolism-type glutamic acid (m-Glu) receptors. The compound or pharmaceutically acceptable salt thereof i

HETEROARYL-PYRAZOLE DERIVATIVE

A compound represented by formula [I] and a pharmaceutically accepted salt of said compound are a novel compound and a pharmaceutically accepted salt thereof which exert antagonistic activity against group II metabotropic glutamate (mGlu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder, etc.), schizophrenia, Alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, sleep disorders, and the like.